Long‐term follow‐up of patients with multiple myeloma treated with total body irradiation—Melphalan conditioning
Since a study published in 2002 showed a survival advantage of melphalan‐only conditioning for stem cell transplantation (HSCT) over melphalan‐total body irradiation (mel‐TBI) in patients with multiple myeloma (MM), most centers abandoned mel‐TBI. Mel‐TBI causes more early toxicity and is more complicated to administer, but we speculated it may result in longer term survival with radiation as an independent treatment modality. Therefore, we analyzed the long‐term outcome of patients with MM who received mel‐TBI as part of conditioning at our center.
No Supplementary Data
No Article Media